Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA: 688192)

China flag China · Delayed Price · Currency is CNY
35.78
-1.81 (-4.82%)
Sep 6, 2024, 4:00 PM CST
11.46%
Market Cap 14.87B
Revenue (ttm) 294.84M
Net Income (ttm) -938.21M
Shares Out 415.65M
EPS (ttm) -2.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,956,102
Open 37.65
Previous Close 37.59
Day's Range 35.52 - 37.79
52-Week Range 24.82 - 54.58
Beta 0.16
Analysts n/a
Price Target n/a
Earnings Date Oct 29, 2024

About Dizal (Jiangsu) Pharmaceutical

Dizal (Jiangsu) Pharmaceutical Co., Ltd. discovers, develops, and commercializes medicines in the areas of cancer and immunological diseases. It develops JAUKPO, which is in Phase II clinical trials for the treatment of hematological malignancy and immunological diseases; DZD8586 that is in Phase I for the treatment of hematological malignancy; ZEGFROVY, which is in Phase II clinical trials for the treatment of solid tumors; DZD1516 that is in Phase II clinical trials for the treatment of solid tumors; and DZD2269, which is in Phase I clinical ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2017
Employees 581
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688192
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.